文献速递肺栓塞与肺血管病

植入式血流动力学传感器监测肺动脉高压

Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor.
PubMed 文献 · Chest · 2019-06-29

本研究在26例纽约心脏协会(NYHA)III或IV级右心衰的肺动脉高压(PAH)患者中植入CardioMEMS HF传感器,通过至少每周回顾每日血流动力学数据指导PAH治疗,随访至4年。结果显示该系统使用安全,无器械相关严重不良事件,植入后1个月内即观察到肺动脉压力显著下降和心输出量升高,1年内NYHA分级和生活质量显著改善。结论认为该系统可为PAH治疗监测提供有用信息,但需更大规模临床试验后方可广泛用于指导重度PAH伴右心衰患者的治疗。

要点

  • CardioMEMS HF系统在PAH伴右心衰患者中短期和长期使用均安全。
  • 植入后1个月内肺动脉压力显著下降、心输出量显著升高。
  • 1年内NYHA分级和生活质量显著改善,但需更大规模试验验证。

核心结论

  • CardioMEMS HF系统可为PAH治疗监测提供有用信息,并显示短期和长期安全性。
  • 在广泛用于指导重度PAH伴右心衰患者治疗前,仍需更大规模临床试验。

研究设计与样本

  • 研究纳入26例PAH伴NYHA III或IV级右心衰患者,年龄51.3 ± 18.3岁,92%为女性,81%为NYHA III级。
  • 植入CardioMEMS HF传感器,通过至少每周回顾每日血流动力学测量来跟踪PAH治疗。
  • 通过门诊随访跟踪安全性、功能反应和血流动力学反应至4年。

主要发现

  • 未观察到器械相关严重不良事件,发生1例植入前严重不良事件。
  • 植入后1个月内即观察到肺动脉压力显著下降和心输出量升高。
  • 1年内观察到NYHA分级和生活质量显著改善。

临床怎么用

  • 对于PAH伴右心衰患者,可考虑使用植入式血流动力学传感器进行远程血流动力学监测以指导治疗。
  • 应用时需至少每周回顾每日血流动力学数据,并结合临床随访评估功能和血流动力学反应。

局限性

  • 研究样本量较小(26例),需更大规模临床试验验证。
  • 研究为可行性及早期安全性评估,尚未确立广泛用于指导治疗的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension (PAH) is a chronic disease that ultimately progresses to right-sided heart failure (HF) and death. Close monitoring of pulmonary artery pressure (PAP) and right ventricular (RV) function allows clinicians to appropriately guide therapy. However, the burden of commonly used methods to assess RV hemodynamics, such as right heart catheterization, precludes frequent monitoring. The CardioMEMS HF System (Abbott) is an ambulatory implantable hemodynamic monitor, previously only used in patients with New York Heart Association (NYHA) class III HF. In this study, we evaluate the feasibility and early safety of monitoring patients with PAH and right-sided HF using the CardioMEMS HF System. METHODS: The CardioMEMS HF sensors were implanted in 26 patients with PAH with NYHA class III or IV right-sided HF (51.3 ± 18.3 years of age, 92% women, 81% NYHA class III). PAH therapy was tracked using a minimum of weekly reviews of CardioMEMS HF daily hemodynamic measurements. Safety, functional response, and hemodynamic response were tracked up to 4 years with in-clinic follow-ups. RESULTS: The CardioMEMS HF System was safely used to monitor PAH therapy, with no device-related serious adverse events observed and a single preimplant serious adverse event. Significant PAP reduction and cardiac output elevation were observed as early as 1 month postimplant using trends of CardioMEMS HF data, coupled with significant NYHA class and quality of life improvements within 1 year. CONCLUSIONS: The CardioMEMS HF System provided useful information to monitor PAH therapy, and demonstrated short- and long-term safety. Larger clinical trials are needed before its widespread use to guide therapy in patients with severe PAH with right-sided HF.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Benza RL, Doyle M, Lasorda D, et al. Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. Chest. 2019. PMID: 31265832. doi:10.1016/j.chest.2019.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。